Bolt Biotherapeutics vs Ocugen
Bolt Biotherapeutics is the larger business, with $7.7m of revenue in fiscal 2025 against $4.4m for Ocugen (1.7 times as much). Ocugen grew faster (8.8% against 0.1%). Bolt Biotherapeutics kept more of each dollar of sales as profit: a net margin of -433.7% against -1537.4%.
| Latest fiscal year | Bolt BiotherapeuticsBOLT, 2025 | OcugenOCGN, 2025 |
|---|---|---|
| Revenue | $7.7m | $4.4m |
| Revenue growth | 0.1% | 8.8% |
| Net income | −$33.4m | −$67.8m |
| Operating margin | -469.3% | -1425.7% |
| Net margin | -433.7% | -1537.4% |
| Return on equity | -79.7% | — |
| Free cash flow | −$39.9m | −$57.1m |
| Cash | $11.7m | $18.6m |
| Total debt | $0 | $31.5m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 23 | 116 |
| Market value | $12.7m | $253m |
| Price vs our value range | — | — |
| Moat score | 12 (Weak) | 8 (Weak) |
| Insider trades, 12 months | 4 buys, 9 sales | 1 buys, 4 sales |